Securing the best price for an out-licensed asset

Biotech Ensysce seeks out-licensing or partnering opportunities around the world for its proprietary abuse and overdose resistant prodrug technologies. Learn how the company has made successful deals faster, without sacrificing due diligence, and negotiated a higher price than what it originally thought it could obtain.

Related posts